Used in cancer research and development of targeted therapies, this antibody binds specifically to VEGFR2 (KDR/CD309), a key receptor involved in angiogenesis—the formation of new blood vessels that tumors rely on for growth and metastasis. By blocking VEGFR2 signaling, it inhibits vascular endothelial growth factor (VEGF)-driven pathways, reducing tumor blood supply and slowing cancer progression. It serves as a reference standard in assays evaluating anti-angiogenic drug candidates, supporting the development of monoclonal antibodies and small molecule inhibitors. Commonly applied in flow cytometry, immunohistochemistry, and in vivo studies to assess target engagement, expression levels, and biological activity in endothelial cells and tumor tissues.